Biotest’s mission, vision and strategy reflect the company’s goals.
At Biotest we work to provide effective help to patients with serious blood or immune diseases and to enable them to lead the most independent and normal lives possible.
Biotest will continue to develop as a global provider of biological pharmaceuticals in the therapeutic areas of haematology, clinical immunology and intensive care medicine.
The Biotest Group has grown its core business continuously over recent years. We want to continue along this path at a faster pace. Sales should reach the threshold of one billion euros by the year 2020.